Axsome Therapeutics (AXSM) Price & Analysis

Compare

2,208 Followers

AXSM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$75.56 - $139.13

Previous CloseN/A

Volume140.83K

Average Volume (3M)607.39K

Market Cap

$5.25B

Enterprise Value$5.08B

Total Cash (Recent Filing)$303.02M

Total Debt (Recent Filing)$215.29M

Price to Earnings (P/E)―

Beta0.99

Next Earnings

Nov 10, 2025

EPS Estimate

-0.83

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding49,901,485

10 Day Avg. Volume624,310

30 Day Avg. Volume607,389

Financial Highlights & Ratios

PEG Ratio-1.03

Price to Book (P/B)71.10

Price to Sales (P/S)10.51

P/FCF Ratio-31.50

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue10.27

Enterprise Value/Gross Profit11.22

Enterprise Value/Ebitda-22.60

Forecast

1Y Price Target

$165.53

Price Target Upside51.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering17

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst's recommendation for AXSM stock remains 'Outperform'.

Financial PerformanceA strong top-line beat, with better than expected revenue for both Auvelity and Sunosi.

Sales GrowthAUVELITY, Axsome's flagship product for treatment of major depressive disorder, showed a 56% increase in prescriptions compared to the year-ago period, and a 15% rise quarter-over-quarter.

Bears Say

Market PerformanceAuvelity prescriptions were slightly down for the week, although this was roughly in-line with the performance of its peers.

Product LaunchSymbravo is tracking below oral CGRP drugs at early launch juncture.

Axsome Therapeutics News

Axsome Therapeutics management to meet with Needham

Meeting to be held in New York on August 12 hosted by Needham. Published first on TheFly –...

4d ago

AXSM

Axsome Therapeutics price target raised to $176 from $173 at BofA

BofA raised the firm’s price target on Axsome Therapeutics (AXSM) to $176 from $173 and keeps a Buy...

10d ago

AXSM

Morning Movers: Wayfair surges following second quarter results

Stock futures rebounded strongly following last Friday’s steep selloff as investors digested a surprisingly weak July jobs report....

11d ago

Axsome Therapeutics reports Q2 EPS (97c), consensus ($1.09)

Reports Q2 revenue $150.042M, consensus $138.02M. “Axsome delivered robust second quarter performance, reflecting strong underlying demand for our...

11d ago

AXSM

Axsome Therapeutics hosts frontiers in Brain Health R&D Day

Axsome Therapeutics (AXSM) will host its Frontiers in Brain Health R&D Day in New York City to review...

25d ago

AXSM

Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on Axsome Therapeutics, with a price target of...

8d ago

AXSM

Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics and keeping the price target...

8d ago

AXSM

Axsome Therapeutics’ Earnings Call Highlights Robust Growth

Axsome Therapeutics Inc. (($AXSM)) has held its Q2 earnings call. Read on for the main highlights of the...

9d ago

AXSM

Axsome Therapeutics Reports Strong Q2 2025 Growth

Axsome Therapeutics Inc. ( ($AXSM) ) has released its Q2 earnings. Here is a breakdown of the information...

10d ago

AXSM

Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating

Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sean Laaman from...

10d ago

AXSM

Optimistic Outlook for Axsome Therapeutics: Strong Financial Performance and Growth Potential Justify Buy Rating

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on AXSM stock, giving a Buy...

10d ago

AXSM

Strong Growth Prospects and Strategic Advancements Propel Axsome Therapeutics to ‘Buy’ Rating

Analyst Joseph Thome of TD Cowen maintained a Buy rating on Axsome Therapeutics, retaining the price target of...

11d ago

AXSM

Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Reinforce Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on AXSM stock, giving a Buy rating today....

11d ago

AXSM

Axsome Therapeutics Reports Strong Q2 2025 Performance

An update from Axsome Therapeutics ( ($AXSM) ) is now available. On August 4, 2025, Axsome Therapeutics reported...

11d ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was $75.56 and its highest was $139.13 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $5.25B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Nov 10, 2025 which is in 87 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on Aug 04, 2025. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.055 by $0.085.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.83.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 49,901,485 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.055. Following the earnings report the stock price went up 3.417%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in AXSM

Axsome Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-280.68%

Trailing 12-Months

Asset Growth

16.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) is a clinical-stage biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS) disorders. The company's primary areas of interest include depression, pain, and addiction, with a robust pipeline of candidates aimed at addressing significant unmet medical needs. Axsome's lead product, AXS-05, is a multimodal investigational drug for the treatment of major depressive disorder and other indications, while AXS-07 is designed for the acute treatment of migraine. Through its innovative approach to drug development, Axsome aims to improve the quality of life for patients with complex CNS conditions.

Axsome Therapeutics (AXSM) Earnings & Revenues

Historic Earnings Reports

AXSM Company Deck

AXSM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected strong revenue growth and successful product performance, particularly for Auvelity and Sunosi. The launch of SYMBRAVO was a notable milestone, despite early challenges in coverage and high discounts. Overall, the company's position in the market and its pipeline progress indicate a promising outlook, though financial losses and coverage hurdles present areas for improvement.View all AXSM earnings summaries

AXSM Stock 12 Month Forecast

Average Price Target

$165.53

▲(51.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"$83","142":"$142","201":"$201","112.5":"$112.5","171.5":"$171.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":165.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$165.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$107.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,112.5,142,171.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,110.47999999999999,117.94,125.39999999999999,132.85999999999999,140.32,147.78,155.24,162.7,170.16,177.62,185.07999999999998,192.54,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,107.82846153846154,112.63692307692307,117.44538461538461,122.25384615384615,127.06230769230768,131.8707692307692,136.67923076923077,141.4876923076923,146.29615384615386,151.10461538461539,155.91307692307691,160.72153846153844,{"y":165.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,103.32615384615384,103.63230769230769,103.93846153846154,104.24461538461539,104.55076923076923,104.85692307692308,105.16307692307691,105.46923076923076,105.77538461538461,106.08153846153846,106.3876923076923,106.69384615384615,{"y":107,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.86,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >